Twist1 is highly expressed in primary and metastatic non-small cell lung cancer (NSCLC), and thus acts as a critical target for lung cancer chemotherapy. In the current study, we investigated the underlying mechanism initiated by silencing of Twist1 that sensitizes NSCLC cells to cisplatin. Silencing of Twist1 triggered ATP depletion, leading to AMP-activated protein kinase (AMPK)-activated mammalian target of rapamycin (mTOR) inhibition in NSCLC cells. AMPK-induced mTOR inhibition, in turn, resulted in downregulation of ribosome protein S6 kinase 1 (S6K1) activity. Downregulation of mTOR/S6K1 reduced Mcl-1 protein expression, consequently promoting sensitization to cisplatin. Overexpression of Mcl-1 reduced PARP cleavage induced by cisplatin and Twist1 siRNA, suggesting that this sensitization is controlled through Mcl-1 expression. Interestingly, cells treated with Twist1 siRNA displayed upregulation of p21
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Subject Category: Cancer Lung cancer remains the leading cause of cancer-related death worldwide. About 80% of all lung cancers are non-small cell lung cancer (NSCLC), including squamous carcinoma, adenocarcinoma and large cell carcinoma, with 450% of these patients presenting with locally advanced or metastatic disease. 1 The 5-year survival rates for advanced NSCLC are only 10-20%, partly due to advanced metastasis. 2 Cisplatin is a commonly used therapeutic agent for advanced NSCLC. However, resistance to cisplatin is a major obstacle in potentially curative treatments for advanced NSCLC. 3 The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates cell growth, cell cycle progression and metabolism. The phosphatidylinositol-3 kinase/AKT signaling pathway activates mTOR, in turn, directly phosphorylating ribosome protein S6 kinase 1 (S6K1) and eIF4E-binding protein 1, both of which are important in the control of protein translation initiation.
4-6 S6K1 phosphorylates S6, which regulates the translation of 5 0 terminal oligopyrimidine mRNAs that encode ribosomal proteins and translation factors. 4EBP1 binds to and prevents eIF4E, initiating cap-dependent translation. mTOR is constitutively activated in a variety of human cancers, including ovarian, pancreatic, as well as lung carcinoma. 7 Thus, mTOR signaling networks have emerged as attractive targets in novel therapeutic anticancer strategies.
Epithelial-to-mesenchymal transition (EMT) is a fundamental biological process by which epithelial cells are converted to mesenchymal cells during embryonic development. This process is characterized by loss of cell polarity, decrease in cell-cell adhesion and gain in migration ability. Recently, the concept of EMT has been extended to tumor migration, invasion and metastasis. 8, 9 The EMT process is controlled by zinc-finger proteins (Snail, Slug, Zeb1 and Zebs/SIP1) and basic helix-loop-helix factors (Twist and E47). 10 Twist is an important inducer of EMT, which downregulates the epithelial cell marker (E-cadherin) and upregulates mesenchymal markers (fibronectin, N-cadherin and vimentin), and promotes cancer invasion and metastasis. 11, 12 Twist expression promotes resistance to apoptosis when cells are challenged with cisplatin in lung and bladder cancer and paclitaxel in prostate cancer. 13 Accordingly, identification of the upstream activators and downstream targets of Twist1 may be critical in determining new therapeutic targets for cancer. In the present study, we showed that knockdown of Twist promotes or sensitizes lung cancer cells to apoptotic death via decreasing mTOR/S6K1-dependent Mcl-1 translation that allows cisplatin to exert its toxic effect. These results suggest that targeting molecular cross-talk between mTOR and EMT regulators may be an effective approach to combat cancer.
Results
Knockdown of Twist1 enhances cisplatin-induced cell death in NSCLC. Twist1 is highly expressed in primary and metastatic NSCLC, 14 and therefore an attractive therapeutic target for lung cancer. Initially, we investigated whether downregulation of Twist1 enhances cisplatin sensitivity in NSCLC cells. Two lung cancer cell lines, A549 and H1299, expressed high levels of Twist1 (Figure 1b) , consistent with previous reports.
14 A549 and H1299 cells were transfected with Twist1 siRNA and exposed to cisplatin at doses of 8 and 6 mM for 24 h, respectively. At these concentrations of cisplatin, the growth inhibitory effects o20% (Figure 1a) . The two Twist1 siRNAs led to a considerable knockdown of mRNA expression in both cell types (Figure 1b ). Twist1 suppression with siRNAs induced a sensitization effect to cisplatin (Figure 1c ) and enhanced PARP cleavage (Figure 1d ). Our results clearly indicate that suppression of Twist1 effectively enhances the sensitivity of NSCLC cells to cisplatin.
Knockdown of Twist1 enhances cell sensitivity to cisplatin through Mcl-1 downregulation. Next, we determined the effect of Twist1 knockdown on clonogenic survival. As shown in Figure 2a , colony formation was significantly reduced in cells transfected with Twist1 siRNA, compared with control siRNA. Silencing Twist1 expression with siRNA had no effect on the expression of EMT-related proteins, (Figure 2b ), suggesting that chemosensitivity induced by Twist1 downregulation is not related to EMT-related protein expression. Recent studies showed that activation of AKT (especially AKT2) by Twist1 is critical for the maintenance of EMT and promotion of invasion 15, 16 and activation of the ERK pathway by EGF has profound feedback on EGFR signaling, which activates EMT via the AKT pathway. 17 We then investigated the effect of AKT Knockdown of Twist1 leads to inhibition of mTOR activity, which has an important role in Mcl-1 downregulation. Next, we investigated the mechanism by which knockdown of Twist1 suppresses Mcl-1 protein expression. Initially, mTOR activity was assessed in cells treated with Twist1 siRNA. Twist1 siRNA induced suppression of mTOR activity, as assessed based on the decrease in phosphorylation of mTOR and the mTOR effectors, S6K and S6, in H1299 cells (Figure 4a) . A recent report showed that mTOR promotes survival through translational control of Mcl-1. 19 Accordingly, we analyzed the Mcl-1 protein level in cells treated with mTOR siRNA. As expected, suppression of mTOR resulted in decreased expression of Mcl-1 protein and enhanced H1299 cell sensitivity to cisplatin (Figures 4b and c) .
S6K1, a downstream target of mTOR, has important roles in cell proliferation, protein translation and cell survival and is thus an effective target for cancer therapy. 20 To ascertain whether S6K1 is involved in the regulation of Mcl-1 expression and consequent cell survival, we transfected cells with S6K1 siRNA, followed by treatment with cisplatin. S6K1 siRNA induced a decrease in Mcl-1 protein, relative to control siRNA (Figure 5a ). Moreover, knockdown of S6K1 enhanced cisplatin-induced cell death (Figures 5b and c) . Overexpression of S6K1 reduced PARP cleavage induced by Twist1 siRNA (Figure 5d ). Based on these results, we propose that mTOR activity is suppressed upon Twist1 knockdown, which is critical for Mcl-1 downregulation.
Knockdown of Twist1 leads to inhibition of mTOR activity through AMP-activated protein kinase (AMPK) activation. mTOR activity is suppressed under conditions of energy deprivation in which depleted ATP levels trigger AMPK activation. 21 We further investigated whether AMPK is involved in mTOR inhibition induced by Twist1 suppression. As shown in Figure 6b , treatment with Twist1 siRNA stimulated phosphorylation of AMPK and the AMPK substrate, acetyl-CoA carboxylase, in A549 and H1299 cells. Moreover, suppression of Twist1 led to a marked increase in the cellular ADP/ATP ratio, indicating a decrease in the ATP content in both cell types (Figure 6a ). To establish the involvement of AMPK in Twist1 siRNA-induced mTOR inhibition, we transfected cells displaying Twist1 downregulation with AMPKa1/2 siRNA. Downregulation of AMPK led to recovery of mTOR activity inhibited by Twist1 siRNA (Figure 6c) . Our results collectively suggest that silencing of Waf1/CIP1 downregulation triggers the cell death to Twist1 siRNA and cisplatin. In view of the earlier finding that increased p21
Waf1/CIP1 expression determines cisplatin resistance in human testicular cancer, 22 we analyzed the p21 Waf1/CIP1 mRNA and protein levels in NSCLC cells treated with cisplatin. As shown in Figures 7a and b, cisplatin induced an increase in the p21
Waf1/CIP1 mRNA and protein levels in a dose-dependent manner. p21
Waf1/CIP1 upregulation by cisplatin was observed, even in p53-defective H1299 cells, suggesting that cisplatin induces p21 expression in a p53-independent manner. Interestingly, p21
Waf1/CIP1 was additionally upregulated by Twist1 siRNA in both cell types, as shown in Figure 7c . We further investigated whether p21
Waf1/CIP1 has a protective role against cisplatin and/or Twist1 knockdown-induced cell death by transfecting cells siRNA. p21 Waf1/CIP1 depletion resulted in enhanced sensitivity of cells to Twist1 siRNA and cisplatin-mediated apoptosis (Figure 7d) , suggesting a role of p21 Waf1/CIP1 in preventing cell death by cisplatin or Twist1 siRNA in NSCLC.
Discussion
In the present study, we demonstrated that: (1) knockdown of Twist1 enhances cisplatin-induced cell death in NSCLC cells, (2) antiapoptotic Mcl-1 is significantly downregulated upon knockdown of Twist1, (3) mTOR activity is suppressed upon Twist1 knockdown, which has an important role in Mcl-1 downregulation, (4) ATP depletion and AMPK activation induced by Twist1 siRNA induces mTOR suppression, (5) p21 Waf1/Cip1 is upregulated in cells treated with cisplatin and/or siRNA targeting Twist1 and (6) suppression of p21Waf1/ CIP1 potentiates cell death induced by cisplatin and/or Twist1 siRNA. To our knowledge, this is the first report to show that cross-talk between EMT regulators and mTOR signaling is implicated in resistance to anticancer drugs in NSCLC.
Cisplatin is an effective anticancer drug widely used to treat various solid tumors, including NSCLC. However, acquirement of resistance is a primary impediment in cancer treatment. 3 Knockdown of Twist1 with specific siRNA sensitized A549 and H1299 NSCLC cells to cisplatin-induced cell death. Our data are consistent with previous study, suggesting that Twist depletion increases A549 cell sensitivity to cisplatin. 23 This sensitizing effect was independent of the p53 status, because efficient sensitization was observed in p53-defective H1299 cells. Mcl-1 protein expression was markedly decreased in cells treated with Twist1 siRNA, compared with other Bcl-2 members (Figure 2b) . Overexpression of Mcl-1 suppressed cell death induced by the Twist1 siRNA and cisplatin combination. These results indicate that downregulation of Mcl-1 has an important role in the sensitizing effect of Twist1 siRNA on cisplatin-induced cell death. Indeed, Mcl-1 has been shown to be a critical survival factor in multiple myeloma as well as NSCLC. 18 Mcl-1 is a highly unstable protein, requiring active protein synthesis to maintain its expression levels. 24 In our experiments, knockdown of Twist1 reduced Mcl-1 protein, but not mRNA levels (Figure 2c ). In this regard, we determined whether mTOR and its downstream factors are involved in sensitization to cisplatin induced by Twist1 knockdown. Unexpectedly, knockdown of Twist1 led to reduced phosphorylation levels of mTOR and S6K1, an mTOR downstream effecter. Downregulation of mTOR and S6K1 with siRNA sensitized cells to cisplatin, consistent with the previous finding that transfection of cisplatin-resistant lung cancer cells with siRNA directed against mTOR restores sensitivity. 25 Importantly, we showed that knockdown of mTOR or S6K1 downregulates the Mcl-1 protein level, which is increased in cisplatin-resistant cells. 26 These results indicate that Mcl-1 is a downstream target of mTOR and S6K1. Furthermore, Mcl-1 may be regulated at the translational level, because the main function of mTOR is to control translation via direct regulation of S6K1 and 4E-BP. This assumption is supported by several lines of evidence showing that Mcl-1 is a potential downstream target of eIF4E that specifically contains a G þ C-rich (470%) 5 0 untranslated region among the antiapoptotic Bcl-2 members. 19, 27, 28 In addition, inhibition of mTOR with rapamycin blocked Mcl-1 protein synthesis, but not that of Bcl-2 or Bcl-xL. 19 Surprisingly, knockdown of Twist1 led to a marked increase in the ADP/ATP ratio, indicating a decrease in ATP content. AMPK is a central cellular energy-sensing system that actively participates in the interaction between metabolism and cancer via regulation of the mTOR pathway. AMPK activation directly phosphorylates and activates TSC2 by enhancing its GAP activity, leading to inhibition of mTOR signaling. 29 Our findings confirmed that knockdown of Twist1 led to AMPK activation and consequently to mTOR inhibition. Downregulation of AMPK using AMPKa1/2 siRNA counteracted the inhibition of mTOR activity by Twist1 siRNA. In the present study, we showed that silencing of Twist1 is associated with ATP depletion, leading to AMPK-activated mTOR inhibition, highlighting a novel underlying mechanism of linking between the Twist1 and mTOR pathways. However, further research is necessary to clarify the precise mechanisms linking knockdown of Twist1 to ATP-depletion-induced AMPK activation.
Several studies have reported that increased p21
Waf1/CIP1 expression is associated with tumor progression and negative prognosis and is related to drug resistance in several tumor types. 30, 31 Our experiments revealed that cisplatin or silencing of Twist1 upregulates p21
Waf1/CIP1 expression at the transcriptional level. This p21 Waf1/CIP1 upregulation was observed in p53-defective H1299 cells, and may thus be independent of p53. Treatment of cells with p21
siRNA enhanced the sensitizing effect of Twist1 silencing on cisplatin-induced cell death. These results indicate that upregulation of p21
Waf1/CIP1 has a protective role against cisplatin or/and Twist1 knockdown-induced cell death, supporting the utility of p21 Waf1/CIP1 as a possible therapeutic target, at least for cisplatin treatment, in NSCLC.
In conclusion, we have demonstrated that silencing of Twist1 sensitizes lung cancer cells to cisplatin. This sensitization is mediated by ATP depletion, resulting in AMPK activation and mTOR/S6K1 inhibition, and culminating in downregulation of the Mcl-1 protein level. Our findings highlight a novel mechanism of sensitization to cisplatininduced cell death linking Twist1 to the mTOR pathway and provide a rationale for the use of Twist1 as a promising therapeutic target in lung cancer treatment. RT-PCR analysis. Total RNA isolation and cDNA synthesis were conducted, as described previously. 32 The following primers were used: Twist1 Plasmids and siRNAs. Full-length Mcl-1 cDNA was cloned into the BamHI/ XbaI sites of pcDNA4 HisMax C (Invitrogen) encoding His. S6K1 cDNA containing an N-terminal Myc (plasmid 26610) was purchased from Addgene (Cambridge, MA, USA). All constructs were verified by DNA sequencing.
Twist1 (no. 1, sc-38604), Mcl-1 (sc-35877), AMPKa1/2 (sc-45312), p21 (sc-29427) and control (no. 1, sc-37007) siRNAs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Twist1 (no. 2, s14523) and control (no. 2, 4611) siRNAs from Ambion (Austin, TX, USA), S6K1 (Hs_RPS6KB1_5) and control (1022076) siRNAs from Qiagen (Valencia, CA, USA) and mTOR (6381) and control (6568) siRNAs from Cell Signaling Technology (Beverly, MA, USA). Waf1/CIP1 siRNA for 24 h, followed by treatment with 6 mM cisplatin for 24 h. The indicated protein and mRNA levels were measured using western blot (a, c and d) and RT-PCR (b and c) analyses. Cell viability was measured with the MTT assay (d). Cell viability of control siRNA (siCTL)-treated group was set at 100%, and survival relative to the siCTL presented. The graph is shown as the mean of each group and error bars reflect S.D. *Po0.05 versus the siTwist1/cisplatin-treated group
